Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
Cantor Fitzgerald
Cipla
Fuji
Baxter
Argus Health

Generated: April 22, 2019

DrugPatentWatch Database Preview

LYRICA CR Drug Profile

« Back to Dashboard

Which patents cover Lyrica Cr, and what generic alternatives are available?

Lyrica Cr is a drug marketed by Pf Prism Cv and is included in one NDA. There are five patents protecting this drug and four Paragraph IV challenges.

This drug has one hundred and four patent family members in forty-five countries.

The generic ingredient in LYRICA CR is pregabalin. There are forty-one drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the pregabalin profile page.

US Patents and Regulatory Information for LYRICA CR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pf Prism Cv LYRICA CR pregabalin TABLET, EXTENDED RELEASE;ORAL 209501-001 Oct 11, 2017 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Pf Prism Cv LYRICA CR pregabalin TABLET, EXTENDED RELEASE;ORAL 209501-003 Oct 11, 2017 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Pf Prism Cv LYRICA CR pregabalin TABLET, EXTENDED RELEASE;ORAL 209501-001 Oct 11, 2017 RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for LYRICA CR
Drugname Dosage Strength RLD Date
➤ Subscribe Extended-release Tablets 82.5 mg and 165 mg ➤ Subscribe ➤ Sign Up
➤ Subscribe Extended-release Tablets 82.5 mg and 165 mg ➤ Subscribe ➤ Sign Up
➤ Subscribe Extended-release Tablets 330 mg ➤ Subscribe ➤ Sign Up
➤ Subscribe Extended-release Tablets 330 mg ➤ Subscribe ➤ Sign Up

Supplementary Protection Certificates for LYRICA CR

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0934061 PA2004017,C0934061 Lithuania ➤ Sign Up PRODUCT NAME: PREGABALINUM ((S)-3-(AMINOMETIL)-5-METILHEKSANO RUGSTIS); REGISTRATION NO/DATE: EU/1/04/279/001-025 20040725
0641330 CA 2004 00036 Denmark ➤ Sign Up
0641330 C00641330/01 Switzerland ➤ Sign Up FORMER REPRESENTANTIVE: E. BLUM AND CO. PATENTANWAELTE, CH
Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Teva
Chinese Patent Office
Baxter
Fuji
US Department of Justice
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.